Physician profile
Raul Weiss
NPI 1063417426
$886,997.66
in general payments reported to CMS, 2019-2025
25 companies · $54K in 2025
The $54K reported for 2025 was more than what 96% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138K · 2020: $116K · 2021: $145K · 2022: $239K · 2023: $118K · 2024: $77K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $206K · Travel and Lodging: $23K · Food and Beverage: $11K · Honoraria: $5,000 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $205,931.25 |
| Travel and Lodging | $22,846.36 |
| Food and Beverage | $10,930.08 |
| Honoraria | $5,000.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $592,547.17 | 2019-2025 | Aveir, Cardiomems, Ensite Precision |
| Boston Scientific Corporation | $80,744.13 | 2019-2025 | General - Therapies, Clinical Trial Product, Watchman Flx |
| Medical Device Business Services, INC. | $72,564.08 | 2019-2021 | |
| Biotronik INC. | $67,970.40 | 2019-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Impulse Dynamics (USA) INC. | $46,242.74 | 2020-2024 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9,837.18 | 2024-2025 | Lifevest |
| Altathera Pharmaceuticals LLC | $4,487.10 | 2022-2025 | Sotalol Hydrochloride |
| Biosense Webster, INC. | $3,650.72 | 2019-2025 | Carto 3, Nuvision Ice Catheter |
| Sanofi-Aventis U.S. LLC | $3,408.00 | 2021 | |
| Ancora Heart, INC. | $2,924.05 | 2023-2024 | Accucinch |
| Medtronic, INC. | $1,380.15 | 2023-2025 | Cobalt Dr Mri Surescan, Abre, Aurora Ev-Icd Mri Surescan |
| Atricure, INC. | $344.86 | 2023 | |
| Philips North America LLC | $287.43 | 2023 | (9520) Igt Devices Und |
| Janssen Pharmaceuticals, INC | $136.22 | 2023-2024 | Xarelto |
| Acutus Medical, INC. | $101.92 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $78.03 | 2023-2025 | Eliquis, Camzyos |
| Volta Medical INC | $71.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $53.32 | 2023-2024 | |
| Bridgebio Pharma, INC. | $31.02 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $29.17 | 2024 | Assure Wcd |
| Pfizer INC. | $26.04 | 2025 | |
| Catheter Precision INC. | $23.75 | 2025 | |
| Baxter Healthcare | $22.38 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Inspire Medical Systems, INC. | $18.34 | 2025 | Inspire |
| Irhythm Technologies, INC. | $17.69 | 2024 | Zio Monitor, Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.